SCHEMBL30199508

SCHEMBL30199508

C[C@@H]1CN(C(=O)OCc2ccccc2)C[C@H](C)N1CCCBr

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 2/20 0.50
SMN1; SMN2 Q16637 3/20 0.48
NPC1 O15118 2/20 0.48
RAB9A P51151 2/20 0.48
PDK1 Q15118 1/20 0.47
PDK2 Q15119 1/20 0.47
PDK3 Q15120 1/20 0.47
PDK4 Q16654 1/20 0.47
CYP2C19 P33261 1/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
CACNA1G O43497 1/20 0.44
CACNA1H O95180 1/20 0.44
CACNA1I Q9P0X4 1/20 0.44
TMEM97 Q5BJF2 4/20 0.42
SIGMAR1 Q99720 4/20 0.42
HTR1A P08908 1/20 0.42
ADRA2A P08913 1/20 0.42
ADRA2B P18089 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30199385 0.89 HTR2C (0.51) HTR2CSMN1; SMN2NPC1RAB9APDK1
SCHEMBL30199651 0.86 HTR2C (0.53) HTR2CSMN1; SMN2NPC1RAB9APDK1
SCHEMBL3662621 0.83 HTR2C (0.58) HTR2CSMN1; SMN2NPC1RAB9APDK1
SCHEMBL31393228 0.83 HTR2C (0.58) HTR2CSMN1; SMN2NPC1RAB9APDK1
SCHEMBL31679608 0.83 HTR2C (0.46) HTR2CSMN1; SMN2NPC1RAB9APDK1
SCHEMBL30199761 0.83 HTR2C (0.46) HTR2CSMN1; SMN2NPC1RAB9APDK1
SCHEMBL14372548 0.79 SMN1; SMN2 (0.60) HTR2CSMN1; SMN2NPC1RAB9APDK1
SCHEMBL16472423 0.79 SMN1; SMN2 (0.60) HTR2CSMN1; SMN2NPC1RAB9APDK1
SCHEMBL15218647 0.79 SMN1; SMN2 (0.60) HTR2CSMN1; SMN2NPC1RAB9APDK1
SCHEMBL29849418 0.77 CHRM1 (0.60) HTR2CSMN1; SMN2NPC1RAB9APDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4171567-B1 CEREBLON BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH CELGENE CORP (US) 2025-09-03 EP disclosed
CN-115968293-A Cereblon binding compounds, compositions thereof, and methods of use thereof for treatment 新基公司 2023-04-14 CN disclosed
US-11560371-B2 Cereblon binding compounds, compositions thereof, and methods of treatment therewith CELGENE CORPORATION (US) 2023-01-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11560371-B2 Cereblon binding compounds, compositions thereof, and methods of treatment therewith CRBN, AR, SHBG HTR2C 946/4885SMN1; SMN2 734/4885NPC1 1516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.